Cargando…
Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model
Renal cell carcinoma (RCC), also called kidney cancer or renal adenocarcinoma, is highly resistant to current treatments. It has been previously reported that a Kunitz-type inhibitor domain-containing protein, isolated from the salivary glands of the Amblyomma cajennense tick, triggers apoptosis in...
Autores principales: | de Souza, Jean Gabriel, Morais, Katia L.P., Anglés-Cano, Eduardo, Boufleur, Pamela, de Mello, Evandro Sobroza, Maria, Durvanei Augusto, Origassa, Clarice Silvia Taemi, Zampolli, Hamilton de Campos, Câmara, Niels Olsen Saraiva, Berra, Carolina Maria, Bosch, Rosemary Viola, Chudzinski-Tavassi, Ana Marisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308724/ https://www.ncbi.nlm.nih.gov/pubmed/27566592 http://dx.doi.org/10.18632/oncotarget.11555 |
Ejemplares similares
-
Dynein Function and Protein Clearance Changes in Tumor Cells Induced by a Kunitz-Type Molecule, Amblyomin-X
por: Pacheco, Mario T. F., et al.
Publicado: (2014) -
Preclinical evaluation of Amblyomin-X, a Kunitz-type protease inhibitor with antitumor activity
por: Maria, Durvanei A., et al.
Publicado: (2018) -
Amblyomin-X, a recombinant Kunitz-type inhibitor, regulates cell adhesion and migration of human tumor cells
por: Schmidt, Mariana Costa Braga, et al.
Publicado: (2018) -
A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production
por: Maria, Durvanei Augusto, et al.
Publicado: (2012) -
Amblyomin-X induces ER stress, mitochondrial dysfunction, and caspase activation in human melanoma and pancreatic tumor cell
por: Morais, Katia L. P., et al.
Publicado: (2016)